Parenteral amdinocillin for treatment of complicated urinary tract infections.
Amdinocillin was administered to 55 male and female patients with complicated urinary tract infections. Forty-eight of these patients (28 men and 20 women) were evaluated to determine the safety and efficacy of amdinocillin. Therapy was instituted intravenously and concluded intramuscularly for a total of 7.8 mean therapy days. Toxicity was negligible and side effects were limited to presumed penicillin-allergic reactions. Escherichia coli was the infecting organism in 60 percent of the patients. In 79 percent of the patients, the infections were cured during therapy and from five to nine days following therapy. It was concluded that amdinocillin is a satisfactory antibiotic for the treatment of complicated urinary tract infections with susceptible organisms.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000560:Amdinocillin / Q000008:administration & dosage* / Q000009:adverse effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D010397:Penicillanic Acid; D000560:Amdinocillin